Dentists in Newport, MN Accepting Medicare
4 Dentists found. Showing 1 - 4
 Dr. Evelyn Shirene Gounili, DDS Dentist - General Practice Medicare: Not Enrolled in Medicare Practice Location: 1590 Hastings Ave, Newport, MN 55055 Phone: 651-459-2387 |
 Dr. Ryan Robert William Cooper, D.D.S Dentist Medicare: Medicare Enrolled Practice Location: 1590 Hastings Ave, Newport, MN 55055 Phone: 651-459-2387 Fax: 651-459-3259 |
Dr. Michael Jay Roscher, DDS Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 1590 Hastings Ave, Newport, MN 55055 Phone: 651-459-2387 |
Dr. Sandra Cole Wilkinson, DDS Dentist - General Practice Medicare: Medicare Enrolled Practice Location: 1590 Hastings Ave, Newport, MN 55055 Phone: 651-459-2387 |
News Archive
Vitamin C to ward off colds - don't bother!
A survey by Australian and Finnish scientists of 30 different scientific studies from around the world over the last twenty years, has reached the conclusion that taking daily doses of vitamin C to ward off colds is a waste of time.
New 3D/4D ultrasound system from MEDISON
MEDISON (CEO: Wongihl Sohn, www.medison.com), has announced the launch of a new dedicated high performance OB/GYN ultrasound system, featuring the industry's first multi-rendering 3D/4D technology, 3D MXI(TM) (3D Multi-eXtended Imaging(TM)) - ACCUVIX V20 'Prestige.'
Rigel reports net loss of $25.6 million in first quarter 2013
Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2013. For the first quarter of 2013, Rigel reported a net loss of $25.6 million, or $0.29 per share, compared to a net loss of $23.2 million, or $0.32 per share, in the first quarter of 2012. Weighted average shares outstanding for the first quarters of 2013 and 2012 were 87.1 million and 71.4 million, respectively.
International clinical study of new drug to treat advanced prostate cancers yields promising results
Today the New England Journal of Medicine published the first results of a phase III international clinical study called TITAN (National Clinical Trials Number 02489318), which evaluated the effectiveness and safety of a new drug, apalutamide, to treat advanced prostate cancers.
› Verified 5 days ago